M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:M12 - DE000A0STSQ8 - Common Stock
17.86 EUR
+0.06 (+0.34%)
Taking everything into account, M12 scores 6 out of 10 in our fundamental rating. M12 was compared to 28 industry peers in the Health Care Providers & Services industry. M12 is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. M12 has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
M12 had positive earnings in the past year.
In the past year M12 had a positive cash flow from operations.
Each year in the past 5 years M12 has been profitable.
M12 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
M12 has a Return On Assets of 8.73%. This is amongst the best in the industry. M12 outperforms 96.97% of its industry peers.
M12's Return On Equity of 15.03% is fine compared to the rest of the industry. M12 outperforms 75.76% of its industry peers.
Looking at the Return On Invested Capital, with a value of 13.44%, M12 belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for M12 is in line with the industry average of 6.91%.
The last Return On Invested Capital (13.44%) for M12 is above the 3 year average (7.72%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROIC | 13.44% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
With an excellent Profit Margin value of 5.00%, M12 belongs to the best of the industry, outperforming 84.85% of the companies in the same industry.
In the last couple of years the Profit Margin of M12 has declined.
With a decent Operating Margin value of 8.52%, M12 is doing good in the industry, outperforming 75.76% of the companies in the same industry.
In the last couple of years the Operating Margin of M12 has declined.
M12 has a Gross Margin of 19.29%. This is in the lower half of the industry: M12 underperforms 60.61% of its industry peers.
M12's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so M12 is creating value.
M12 has less shares outstanding than it did 1 year ago.
M12 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, M12 has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.69 indicates that M12 is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.69, M12 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
M12 has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
M12 has a Debt to FCF ratio of 0.70. This is amongst the best in the industry. M12 outperforms 100.00% of its industry peers.
M12 has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.05, M12 belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 5.69 |
ROIC/WACC1.86
WACC7.21%
2.3 Liquidity
M12 has a Current Ratio of 2.06. This indicates that M12 is financially healthy and has no problem in meeting its short term obligations.
M12 has a better Current ratio (2.06) than 90.91% of its industry peers.
M12 has a Quick Ratio of 1.35. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
M12 has a Quick ratio of 1.35. This is amongst the best in the industry. M12 outperforms 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
M12 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.36%, which is quite good.
M12 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.97% yearly.
The Revenue has been growing slightly by 6.52% in the past year.
Measured over the past years, M12 shows a very strong growth in Revenue. The Revenue has been growing by 34.44% on average per year.
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
3.2 Future
Based on estimates for the next years, M12 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.18% on average per year.
Based on estimates for the next years, M12 will show a quite strong growth in Revenue. The Revenue will grow by 8.24% on average per year.
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.00, which indicates a rather expensive current valuation of M12.
The rest of the industry has a similar Price/Earnings ratio as M12.
M12's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.92.
Based on the Price/Forward Earnings ratio of 15.39, the valuation of M12 can be described as correct.
M12's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 23.46. M12 is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19 | ||
| Fwd PE | 15.39 |
4.2 Price Multiples
60.61% of the companies in the same industry are more expensive than M12, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, M12 is valued a bit cheaper than 60.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.14 | ||
| EV/EBITDA | 8.78 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates M12 does not grow enough to justify the current Price/Earnings ratio.
M12 has a very decent profitability rating, which may justify a higher PE ratio.
M12's earnings are expected to grow with 19.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.66
PEG (5Y)2.39
EPS Next 2Y14.78%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.80%, M12 has a reasonable but not impressive dividend return.
M12's Dividend Yield is rather good when compared to the industry average which is at 1.47. M12 pays more dividend than 87.88% of the companies in the same industry.
M12's Dividend Yield is a higher than the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.8% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.18%
FRA:M12 (12/23/2025, 7:00:00 PM)
17.86
+0.06 (+0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap350.77M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85
Price Target27.03 (51.34%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.8% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19 | ||
| Fwd PE | 15.39 | ||
| P/S | 0.99 | ||
| P/FCF | 13.14 | ||
| P/OCF | 12.97 | ||
| P/B | 2.97 | ||
| P/tB | 12.77 | ||
| EV/EBITDA | 8.78 |
EPS(TTM)0.94
EY5.26%
EPS(NY)1.16
Fwd EY6.5%
FCF(TTM)1.36
FCFY7.61%
OCF(TTM)1.38
OCFY7.71%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)3.66
PEG (5Y)2.39
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROCE | 19.39% | ||
| ROIC | 13.44% | ||
| ROICexc | 18.99% | ||
| ROICexgc | 105.66% | ||
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% | ||
| FCFM | 7.52% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 21.13 | ||
| Cash Conversion | 76.34% | ||
| Profit Quality | 150.51% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.69 |
F-Score9
WACC7.21%
ROIC/WACC1.86
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year30.73%
EBIT Next 3Y27.49%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A
M1 KLINIKEN AG / M12.DE FAQ
Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?
ChartMill assigns a fundamental rating of 6 / 10 to M12.DE.
Can you provide the valuation status for M1 KLINIKEN AG?
ChartMill assigns a valuation rating of 4 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.
How profitable is M1 KLINIKEN AG (M12.DE) stock?
M1 KLINIKEN AG (M12.DE) has a profitability rating of 6 / 10.
What are the PE and PB ratios of M1 KLINIKEN AG (M12.DE) stock?
The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 19 and the Price/Book (PB) ratio is 2.97.